2025
Current cutting-edge omics techniques on musculoskeletal tissues and diseases
Li X, Fang L, Zhou R, Yao L, Clayton S, Muscat S, Kamm D, Wang C, Liu C, Qin L, Tower R, Karner C, Guilak F, Tang S, Loiselle A, Meyer G, Shen J. Current cutting-edge omics techniques on musculoskeletal tissues and diseases. Bone Research 2025, 13: 59. PMID: 40484858, PMCID: PMC12146411, DOI: 10.1038/s41413-025-00442-z.Peer-Reviewed Original ResearchConceptsDisease-associated alterationsImpact quality of lifeIntervertebral disc degenerationMusculoskeletal tissuesMolecular landscapeDisc degenerationQuality of lifeBone fracturesRheumatoid arthritisBulk transcriptomesTherapeutic targetTissue microenvironmentClinical applicationPathophysiological processesDisease mechanismsEconomic burdenMusculoskeletal disordersImpact qualityOmics technologiesMulti-omics integrationDiseaseSingle-cellTissueSpatial organization of cellsCellular heterogeneityStandardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors
Raskin N, Hiligsmann M, Rebutoc A, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall D, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood G. Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors. Seminars In Arthritis And Rheumatism 2025, 74: 152769. PMID: 40544704, DOI: 10.1016/j.semarthrit.2025.152769.Peer-Reviewed Original ResearchHealth outcome descriptorsPatient decision aidsHealth outcomesPatient-important outcomesPatient preference studiesOutcome descriptorsThematic content analysisOutcome descriptionsNarrative summaryPreference studiesPtDAsRA outcomesAuthor consensusRheumatoid arthritisData extractionModifying drug therapySymptoms patientsContent analysisAdverse eventsDrug therapyDisease modifying drug therapyLack of descriptionHealthOutcomesAIDSValidation of the Coping with Health Injuries and Problems questionnaire in a longitudinal cohort with recent-onset rheumatoid arthritis
Akman Z, Boire G, Carrier N, Roux S, Masetto A, de Brum-Fernandes A, Liang P, Allard-Chamard H. Validation of the Coping with Health Injuries and Problems questionnaire in a longitudinal cohort with recent-onset rheumatoid arthritis. Rheumatology Advances In Practice 2025, rkaf057. DOI: 10.1093/rap/rkaf057.Peer-Reviewed Original ResearchInternal consistencyTreatment adherenceBack pain patientsHealth injuriesYears of follow-upFollow-upCohort of early rheumatoid arthritisCronbach's alphaPain patientsDiagnosed RA patientsIndividual coping stylesRheumatoid arthritisFollow-up visitPsychometric propertiesCoping stylesLongitudinal cohortRecent-onset rheumatoid arthritisConfirmatory factor analysisProspective cohortInstrument itemsSubscalesProblems QuestionnaireRA patientsFactor structureEarly rheumatoid arthritisP112 Cytokine driven disease and epigenetic heterogeneity in rheumatoid arthritis
Hughes S, Costa D, Soria A, Hill D, Figueras A, Scott R, Dimonte S, Monaco F, Jenkins R, Twohig J, Guy C, Cossins B, Andrews R, Szomolay B, Choy E, Vinh N, Lewis M, Jenkins B, Turner S, Tiganis T, Williams N, Yu H, Pitzalis C, Jones G, Jones S. P112 Cytokine driven disease and epigenetic heterogeneity in rheumatoid arthritis. Rheumatology 2025, 64: keaf142.152. DOI: 10.1093/rheumatology/keaf142.152.Peer-Reviewed Original ResearchEctopic lymphoid-like structuresAntigen-induced arthritisRNA-seqTransposase-accessible chromatin (ATAC)-seqRheumatoid arthritisChromatin immunoprecipitation (ChIP)-seqTreatment of immune-mediated inflammatory diseasesClinical response to therapyCytokine signalingSynovial biopsiesImmune-mediated inflammatory diseasesSmall-needle biopsiesLymphoid-like structuresResponse to therapyNature of pathologyWT miceEpigenetic heterogeneityNeedle biopsyTargeting cytokine signallingGenomic signaturesImmune pathologyNGS methodSTAT3 activationTranscription factorsEpigenetic regulationA series of hydroxychloroquine-associated cardiotoxicity presenting with heart failure
Nazarenko N, Maliha M, Parker M, Borkowski P, Csecs I, Tauras J, Shin J, Pullman J, Sims D, Rochlani Y. A series of hydroxychloroquine-associated cardiotoxicity presenting with heart failure. Annals Of Medicine And Surgery 2025, 87: 1334-1340. PMID: 40213182, PMCID: PMC11981468, DOI: 10.1097/ms9.0000000000002997.Peer-Reviewed Original ResearchSystemic lupus erythematosusHCQ useHeart failureCardiac abnormalitiesCardiac magnetic resonance imagingDose-dependent complicationsRheumatoid arthritisCases of SLE patientsDiscontinuation of hydroxychloroquineResolution of symptomsLong-term therapyEarly detectionShortness of breathA-V blockHCQ therapyMagnetic resonance imagingPrompt discontinuationEndomyocardial biopsyPulmonary hypertensionEjection fractionHF therapyCardiac symptomsImprove patient outcomesSLE patientsSjogren's syndromeChikungunya Fever and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Amaral J, Schoen R, Weinblatt M, Cândido E. Chikungunya Fever and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Tropical Medicine And Infectious Disease 2025, 10: 54. PMID: 39998058, PMCID: PMC11861052, DOI: 10.3390/tropicalmed10020054.Peer-Reviewed Original ResearchChikungunya virus infectionRheumatoid arthritisChikungunya virusChikungunya feverChronic chikungunya arthritisRheumatology follow-upIncidence of RARisk of biasChikungunya arthritisAutoimmune mechanismsImmunological mechanismsFollow-upRA incidenceRA diagnosisDiagnostic criteriaRA developmentInfectionPRISMA guidelinesRe-emerging infectious diseasesLiterature searchDiagnostic biomarkersLong-term health impactsData extractionInfectious diseasesIncidenceDistinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity
Sánchez-Zuno G, Bucala R, Hernández-Bello J, Palafox-Sánchez C, Vizcaíno-Quirarte A, Muñoz-Valle J. Distinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity. Journal Of Interferon & Cytokine Research 2025, 45: 99-106. PMID: 39914814, PMCID: PMC12021775, DOI: 10.1089/jir.2024.0184.Peer-Reviewed Original ResearchConceptsMigration inhibitory factorMigration inhibitory factor levelsDisease activityRA patientsControl subjectsRheumatoid arthritisLevels of migration inhibitory factorSerum levels of CXCL12Levels of CXCL12Serum of RA patientsModerate disease activityMembranous expression patternRheumatoid factor titerMIF levelsCXCL12 levelsSerum levelsCXCL8 levelsSoluble biomarkersTreatment protocolsPattern of expressionSerum CXCL8PatientsReceptor patternsClinical biomarkersInhibitory factorPtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans
Hernández-Bello J, Bach H, Cerpa-Cruz S, Sánchez-Zuno G, Hernández-Gutiérrez R, Nicoletti F, Saraceno A, Muñoz-Valle J. PtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans. PLOS ONE 2025, 20: e0316727. PMID: 39752467, PMCID: PMC11698356, DOI: 10.1371/journal.pone.0316727.Peer-Reviewed Original ResearchConceptsMycobacterium avium subspecies paratuberculosisControl subjectsVirulence factorsRA patientsBattery of virulence factorsRheumatoid arthritisProtein tyrosine phosphatase ADisease activityPhago-lysosome fusionModerate to high disease activityHigh disease activityDisease Activity ScoreMale control subjectsIndirect ELISA methodMycobacterium avium subspecies paratuberculosis infectionMycobacterium avium subspPhosphatase AMarkers of rheumatoid arthritisIntracellular pathogensPTPAMedian ODActivity scoreProteinELISA methodPatients
2024
Fetal Growth Associated with Maternal Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Chock E, Glintborg B, Liew Z, Pedersen L, Thunbo M. Fetal Growth Associated with Maternal Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. Healthcare 2024, 12: 2390. PMID: 39685012, PMCID: PMC11641325, DOI: 10.3390/healthcare12232390.Peer-Reviewed Original ResearchJuvenile idiopathic arthritisEstimated Fetal WeightRheumatoid arthritisGestational ageIdiopathic arthritisMaternal RAWeeks of gestational ageFetal growth indicatorsFetal Medicine DatabasePregnancies of patientsEvaluate fetal growthInternational Classification of Diseases-10 codesAssociated with SGAFetal biometric measurementsAdverse pregnancy outcomesLow birth weightPopulation-based cohort studyFetal ultrasound scanOffspring of patientsNational Patient RegistrySingleton pregnanciesPregnant patientsZ-score differenceFetal weightPreterm birthWorldwide Clinical and Real-World Exposure to Baricitinib
Vleugels R, Craiglow B, Mostaghimi A, Olsen E, Sontag A, Denning K, Somani N, Hordinsky M. Worldwide Clinical and Real-World Exposure to Baricitinib. SKIN The Journal Of Cutaneous Medicine 2024, 8: s501. DOI: 10.25251/skin.8.supp.501.Peer-Reviewed Original ResearchLength of therapyClinical trialsAtopic dermatitisTreated with baricitinibAverage length of therapyAge 2 yearsJuvenile idiopathic arthritisYears of ageMonths of ageBaricitinib doseAverage daily doseYrs of agePediatric patientsAcute infectious diseaseDaily doseCOVID-19 infectionAlopecia areataJAK inhibitorsHospitalized patientsIdiopathic arthritisBaricitinibPatientsBlind trialRheumatoid arthritisDisease statesVersatility of 14-3-3 proteins and their roles in bone and joint-related diseases
Zhou R, Hu W, Ma P, Liu C. Versatility of 14-3-3 proteins and their roles in bone and joint-related diseases. Bone Research 2024, 12: 58. PMID: 39406741, PMCID: PMC11480210, DOI: 10.1038/s41413-024-00370-4.Peer-Reviewed Original ResearchMacrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization
Zhou R, Xue S, Cheng Y, Chen Y, Wang Y, Xing J, Liu H, Xu Y, Lin Y, Pei Z, Wei X, Ding J, Li S, Wang K, Yao F, Zhao Y, Ding C, Hu W. Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization. Journal Of Nanobiotechnology 2024, 22: 578. PMID: 39300463, PMCID: PMC11414146, DOI: 10.1186/s12951-024-02822-9.Peer-Reviewed Original ResearchConceptsCollagen-induced arthritisNanotherapeutic systemInflamed jointsRheumatoid arthritisMacrophage polarizationModulating macrophage polarizationDelay disease progressionDebilitating autoimmune diseaseChronic joint inflammationComprehensive in vitroAnti-inflammatory M2 phenotypeReduced synovial inflammationEnhanced cellular uptakeIntra-articular injectionRheumatoid arthritis treatmentPro-inflammatory M1Treatment optionsAutoimmune diseasesRepolarize macrophagesBiomimetic nanoparticlesDisease progressionMouse modelNanoparticlesTherapeutic strategiesSide effects683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study
Bunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.Peer-Reviewed Original ResearchRisk of MACEModerate-to-severe diseaseIncidence of MACEMACE riskAdverse cardiovascular eventsAtopic dermatitisMatched ControlsRheumatoid arthritisCardiovascular diseaseCardiovascular eventsModerate-to-severe atopic dermatitisAssociated with increased MACE riskRelative risk of MACEMultivariate Cox proportional hazards modelRelative riskCohort entry dateModerate-to-severe ADHistory of cardiovascular diseaseAssociated with multiple comorbiditiesIncreased MACE riskHistory of smokingChronic systemic inflammationFollow-up periodCox proportional hazards modelsUS administrative claims data681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Vleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of malignancyModerate-to-severe diseaseCohort entry dateAtopic dermatitisRheumatoid arthritisFollow-upModerate-to-severe atopic dermatitisSkin cancerNon-AD cohortIncidence of malignancyNonmelanoma skin cancerSubgroup of patientsNon-AD controlsFollow-up periodCox proportional hazards modelsChronic liver diseaseEffect of disease activityInternational Classification of Diseases (ICD)-9Population-based studyProportional hazards modelClinformatics Data MartSystemic therapyClaims-based studyOptum Clinformatics Data Mart697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data
Lebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of non-melanoma skin cancerModerate-to-severe diseaseAtopic dermatitisNon-AD cohortRheumatoid arthritisControl cohortNon-melanoma skin cancer riskModerate-to-severe atopic dermatitisNon-melanoma skin cancer incidenceMultivariate Cox proportional hazards modelSkin cancerModerate-to-severe ADCohort entry dateSquamous cell carcinomaMatched control cohortIntermittent sun exposureFollow-up timeNon-AD controlsRetrospective observational studyCox proportional hazards modelsEffect of disease activityPopulation-based studyProportional hazards modelClinformatics Data MartNS8593 inhibits chondrocyte ferroptosis and alleviates cartilage injury in rat adjuvant arthritis through TRPM7 / HO-1 pathway
Hao W, Zhu R, Zhang H, Chen Y, Li S, Zhou F, Hu W, Zhou R. NS8593 inhibits chondrocyte ferroptosis and alleviates cartilage injury in rat adjuvant arthritis through TRPM7 / HO-1 pathway. The International Journal Of Biochemistry & Cell Biology 2024, 174: 106618. PMID: 39053766, DOI: 10.1016/j.biocel.2024.106618.Peer-Reviewed Original ResearchTransient receptor potential melastatin 7Inhibit TRPM7 channelsHeme oxygenase-1TRPM7 channelsTRPM7 inhibitorRheumatoid arthritisHeme oxygenase-1 pathwayRat adjuvant arthritisExpression of heme oxygenase-1Treatment of RAChondrocyte ferroptosisFerroptosis inducer erastinIn vitro modelCartilage destructionAA ratsNS8593Oxidative stress injuryRestoring redox balanceArticular cartilage damageAdjuvant arthritisPotential novel drugOxygenase-1Restored cell viabilityArticular cartilage destructionReduced cytotoxicityNovel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity
Sahu D, Gupta C, Yennamalli R, Sharma S, Roy S, Hasan S, Gupta P, Sharma V, Kashyap S, Kumar S, Dwivedi V, Zhao X, Panda A, Das H, Liu C. Novel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity. Scientific Reports 2024, 14: 12935. PMID: 38839973, PMCID: PMC11153517, DOI: 10.1038/s41598-024-63790-6.Peer-Reviewed Original ResearchConceptsProtein-protein interactionsGel mobility-shift assaysCollagen-induced arthritisMobility-shift assaysCell surface receptorsFluorescence-activated cell sortingSequence strandsBinding of TNFIn silico methodsCell deathMouse modelSurface receptorsNuclear translocationTrimer formationCell culture assaysRheumatoid arthritisVicious cycle of inflammationModel of collagen-induced arthritisTumor necrosis factor-aCell sortingMouse model of collagen-induced arthritisA549 cellsCycle of inflammationInflammatory bone destructionCulture assayComorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis
Crowson C, Atkinson E, Kronzer V, Kimbrough B, Arment C, Peterson L, Wright K, Mason T, Bekele D, Davis J, Myasoedova E. Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis. Annals Of The Rheumatic Diseases 2024, 83: 556-563. PMID: 38331589, PMCID: PMC11017091, DOI: 10.1136/ard-2023-225093.Peer-Reviewed Original ResearchRA disease activityStandardised mortality ratioPrevalence of depressionRheumatoid arthritisPopulation-based studyEight-county regionDisease activityComorbidity patternsMortality ratioDisease-modifying antirheumatic drugsPrevalence dateVital statusCluster patientsLatent class analysisComorbidity clustersAssess mortalityGeneral populationRA prognosisOlder patientsAntirheumatic drugsComorbiditiesPatient phenotypesClass analysisComorbidityPatientsTRPM7 facilitates fibroblast-like synoviocyte proliferation, metastasis and inflammation through increasing IL-6 stability via the PKCα-HuR axis in rheumatoid arthritis
Lin Y, Chen Y, Hu W, Liu X, Hao W, Xing J, Ding J, Xu Y, Yao F, Zhao Y, Wang K, Li S, Yu Q, Hu W, Zhou R. TRPM7 facilitates fibroblast-like synoviocyte proliferation, metastasis and inflammation through increasing IL-6 stability via the PKCα-HuR axis in rheumatoid arthritis. International Immunopharmacology 2024, 132: 111933. PMID: 38581988, DOI: 10.1016/j.intimp.2024.111933.Peer-Reviewed Original ResearchConceptsTransient receptor potential melastatin 7Rheumatoid arthritisInhibition of transient receptor potential melastatin 7Human RA patientsSynovial hyperplasiaAdjuvant-induced arthritis ratsIncreased TRPM7 expressionIL-6 mRNATreatment of RAPathogenesis of RAFibroblast-like synoviocytesTRPM7 silencingProgression of rheumatoid arthritisTRPM7 expressionChannel inhibitionCation channelsRA patientsMetastasisPharmacological inhibitionArthritis ratsInflammationNuclear translocationSynoviocyte proliferationHyperplasiaProliferationAssociation between sinusitis and incident rheumatic diseases: a population-based study
Kronzer V, Davis J, Hanson A, Sparks J, Myasoedova E, Duarte-Garcia A, Hinze A, Makol A, Koster M, Vassallo R, Warrington K, Wright K, Crowson C. Association between sinusitis and incident rheumatic diseases: a population-based study. RMD Open 2024, 10 PMCID: PMC10806468, DOI: 10.1136/rmdopen-2023-003622.Peer-Reviewed Original ResearchAssociated with increased riskElectronic health record historyPopulation-based case-control studyPopulation-based studyRheumatic disease casesLogistic regression modelsCase-control studyRheumatic diseasesEstimate ORsIncidence of rheumatic diseasesNever smokersDiagnosis codesPrimary exposureAssociated with increased incidenceRegression modelsHigh riskMatched ControlsDisease groupDisease casesAssociationDisease onsetIncidenceRiskRheumatoid arthritisNever
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply